| 2022-10-24 | +66.5% | legal | SEC EDGAR | PCVX 8-K: 8.01 and (SEC Filing) |
| 2022-10-24 | +66.5% | news | InvestorPlace | Why Is Vaxcyte (PCVX) Stock Up 70% Today? - InvestorPlace |
| 2025-03-31 | -54.6% | earnings | Seeking Alpha | Russell 2000 stumbles nearly 10% in Q1 – how biggest IWM ETF holdings fared |
| 2025-03-31 | -54.6% | news | Seeking Alpha | Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer |
| 2025-03-31 | -54.6% | executive | Seeking Alpha | Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity |
| 2025-03-31 | -54.6% | legal | Seeking Alpha | How Peter Marks' FDA departure is impacting pharma, biotech stocks |
| 2025-03-31 | -54.6% | executive | Seeking Alpha | Biggest stock movers Monday: COOP, HSMT, CYRX, PCVX, MRNA, NNOX and more |
| 2025-03-31 | -54.6% | news | Seeking Alpha | Vaxcyte plunges despite pneumonia shot results as Marks departure weighs |
| 2025-03-31 | -54.6% | legal | SEC EDGAR | PCVX 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-03-31 | -54.6% | executive | Seeking Alpha | Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (NASDAQ:PCVX) - Seeking Alpha |
| 2025-03-31 | -54.6% | news | Seeking Alpha | Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (NASDAQ:PCVX) - Seeking Alpha |
| 2025-03-30 | -46.3% | news | Yahoo Finance | Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now - Yahoo Finance |
| 2024-09-03 | +37.4% | legal | SEC EDGAR | PCVX 8-K: 7.01, 8.01 (SEC Filing) |
| 2023-04-17 | +20.4% | legal | SEC EDGAR | PCVX 8-K: 8.01 and (SEC Filing) |
| 2021-05-11 | +16.5% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2025-05-06 | -15.0% | legal | Seeking Alpha | Vinay Prasad to head FDA division regulating vaccines |
| 2024-01-31 | +12.5% | legal | SEC EDGAR | PCVX 8-K: 8.01 and (SEC Filing) |
| 2025-08-06 | -11.7% | earnings | Seeking Alpha | Vaxcyte GAAP EPS of -$1.22 misses by $0.04 |
| 2025-08-06 | -11.7% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2025-07-08 | +11.3% | earnings | Yahoo Finance | Here’s Why Vaxcyte (PCVX) Sold Off in Q1 - Yahoo Finance |
| 2025-01-15 | +10.8% | news | Seeking Alpha | Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy |
| 2025-01-15 | +10.8% | news | Seeking Alpha | Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy (NASDAQ:PCVX) - Seeking Alpha |
| 2022-01-13 | -10.3% | legal | SEC EDGAR | PCVX 8-K: 8.01 and (SEC Filing) |
| 2025-12-01 | -9.6% | news | Seeking Alpha | Vaxcyte, Inc. (PCVX) Presents at Jefferies London Healthcare Conference 2025 - Slideshow |
| 2025-12-01 | -9.6% | legal | Seeking Alpha | Moderna, vaccine makers decline following FDA official comments on future approvals |
| 2025-12-01 | -9.6% | news | Benzinga | CleanSpark, Cipher Mining, Bitdeer Technologies And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga |
| 2025-09-30 | +9.0% | news | Seeking Alpha | Vaxcyte teams up with Thermo Fisher to ensure future vaccine production |
| 2025-09-30 | +9.0% | legal | SEC EDGAR | PCVX 8-K: 1.01 (SEC Filing) |
| 2025-09-30 | +9.0% | news | Yahoo Finance | What Does Wall Street Think About Vaxcyte (PCVX)? - Yahoo Finance |
| 2025-12-19 | +8.7% | legal | SEC EDGAR | PCVX 8-K: 5.02 and (SEC Filing) |
| 2022-05-09 | -8.4% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2025-11-10 | +7.8% | analyst | Yahoo Finance | TD Cowen Reiterates “Buy” Rating on Vaxcyte (PCVX) With $50 PT - Yahoo Finance |
| 2022-02-28 | +7.3% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2026-02-18 | +7.2% | analyst | Insider Monkey | Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating - Insider Monkey |
| 2025-11-14 | +7.1% | news | StocksToTrade | Vaxcyte’s Stock Juggle: Opportunity or Risk? - StocksToTrade |
| 2025-05-08 | +6.9% | earnings | Seeking Alpha | Vaxcyte GAAP EPS of -$1.04 beats by $0.27 |
| 2022-04-18 | -6.9% | legal | SEC EDGAR | PCVX 8-K: 1.01 (SEC Filing) |
| 2022-12-20 | +6.8% | legal | SEC EDGAR | PCVX 8-K: 1.01 (SEC Filing) |
| 2024-11-12 | -6.5% | legal | Seeking Alpha | Vaxcyte gets FDA Breakthrough Therapy Designation for its pneumococcal disease treatment |
| 2025-05-07 | +6.4% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2024-11-05 | -6.0% | earnings | Seeking Alpha | Vaxcyte GAAP EPS of -$0.83 beats by $0.31 |
| 2024-11-05 | -6.0% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2021-10-28 | +5.1% | legal | SEC EDGAR | PCVX 8-K: 5.02 (SEC Filing) |
| 2025-11-04 | -5.0% | earnings | Seeking Alpha | Vaxcyte GAAP EPS of -$1.56 misses by $0.25 |
| 2025-11-04 | -5.0% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2025-06-10 | -5.0% | news | Seeking Alpha | Vaxcyte: Sentiment Is Pushing The Shares Down |
| 2025-06-10 | -5.0% | news | Seeking Alpha | Vaxcyte: Sentiment Is Pushing The Shares Down (NASDAQ:PCVX) - Seeking Alpha |
| 2024-02-27 | -4.9% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2025-02-26 | -4.9% | earnings | Seeking Alpha | Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript |
| 2025-02-26 | -4.9% | earnings | Seeking Alpha | Vaxcyte, Inc. 2024 Q4 - Results - Earnings Call Presentation |
| 2025-02-26 | -4.9% | news | Yahoo Finance | Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds - Yahoo Finance |
| 2025-02-26 | -4.9% | earnings | Seeking Alpha | Vaxcyte, Inc. 2024 Q4 - Results - Earnings Call Presentation (NASDAQ:PCVX) 2025-02-26 - Seeking Alpha |
| 2022-12-12 | +4.8% | legal | SEC EDGAR | PCVX 8-K: 5.02 (SEC Filing) |
| 2026-01-29 | +4.8% | expansion | Seeking Alpha | Vaxcyte launches proposed $500M public offering of stock, warrants |
| 2026-01-29 | +4.8% | news | Stock Titan | Vaxcyte moves to raise $500M with new stock and warrants - Stock Titan |
| 2026-01-29 | +4.8% | news | Quiver Quantitative | Vaxcyte, Inc. Initiates $500 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative |
| 2026-01-29 | +4.8% | news | Stock Titan | Vaxcyte sells 11M new shares in $550M stock offering at $50 - Stock Titan |
| 2026-01-29 | +4.8% | news | GlobeNewswire | Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire |
| 2026-01-29 | +4.8% | expansion | Investing.com | Vaxcyte launches $500 million public offering of common stock - Investing.com |
| 2026-01-29 | +4.8% | news | GlobeNewswire | Vaxcyte Announces Pricing of $550 Million Public Offering - GlobeNewswire |
| 2026-01-29 | +4.8% | expansion | MSN | Vaxcyte launches proposed $500M public offering of stock, warrants - MSN |
| 2026-01-05 | -4.7% | news | DirectorsTalk Interviews | Vaxcyte, Inc. (PCVX) Stock Analysis: Biotech Innovator With Nearly 100% Upside Potential - DirectorsTalk Interviews |
| 2021-08-11 | +4.5% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2022-10-27 | +4.4% | legal | SEC EDGAR | PCVX 8-K: 8.01 and (SEC Filing) |
| 2026-02-02 | +4.4% | legal | SEC EDGAR | PCVX 8-K: 8.01 and (SEC Filing) |
| 2026-02-02 | +4.4% | news | Investing.com | Vaxcyte closes $632.5 million public offering of common stock - Investing.com |
| 2026-02-02 | +4.4% | analyst | GuruFocus | Guggenheim Reiterates Buy Rating on Vaxcyte (PCVX) at $116 Targe - GuruFocus |
| 2025-12-02 | +4.3% | news | Zacks Investment Research | Should I buy Vaxcyte (PCVX) - Zacks Investment Research |
| 2021-11-10 | +4.2% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2023-05-08 | +4.1% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2025-04-10 | +4.0% | news | Yahoo Finance | Vaxcyte Stock Plummets 56% in a Month: Here's the Reason - Yahoo Finance |
| 2026-02-19 | +3.7% | news | Yahoo Finance | Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials - Yahoo Finance |
| 2024-05-08 | -3.5% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2025-05-01 | -3.5% | legal | SEC EDGAR | PCVX 8-K: 5.02 (SEC Filing) |
| 2024-09-06 | +3.4% | legal | SEC EDGAR | PCVX 8-K: 8.01 and (SEC Filing) |
| 2024-09-06 | +3.4% | news | Seeking Alpha | Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy (PCVX) - Seeking Alpha |
| 2025-10-13 | -3.4% | news | Seeking Alpha | ClearBridge SMID Cap Growth Strategy adds CRDO, RKLB, exits OSCR, RARE |
| 2022-08-16 | -3.3% | analyst | TradingView | PCVX Forecast — Price Target — Prediction for 2027 - TradingView |
| 2024-08-06 | -3.3% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2025-02-25 | -3.3% | earnings | Seeking Alpha | Vaxcyte GAAP EPS of -$3.80 beats by $0.27 |
| 2025-02-25 | -3.3% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2025-12-11 | +3.2% | news | Insider Monkey | Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension - Insider Monkey |
| 2025-04-05 | +3.1% | news | Seeking Alpha | Top 10 Russell 2000 weekly gainers and losers as Wall Street crashes |
| 2026-02-24 | +3.0% | earnings | Seeking Alpha | Vaxcyte GAAP EPS of -$5.63 misses by $4.06 |
| 2026-02-24 | +3.0% | legal | SEC EDGAR | PCVX 8-K: 8.01 and (SEC Filing) |
| 2026-02-24 | +3.0% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2026-02-24 | +3.0% | expansion | TipRanks | Vaxcyte Launches New $500 Million ATM Equity Program - TipRanks |
| 2022-11-07 | +2.7% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2025-11-19 | -2.6% | news | Seeking Alpha | Vaxcyte, Inc. (PCVX) Presents at Jefferies London Healthcare Conference 2025 Transcript |
| 2026-04-23 | -2.6% | news | Insider Monkey | Vaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial Stage |
| 2026-04-23 | -2.6% | news | Yahoo Finance | Vaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial Stage - Yahoo Finance |
| 2026-04-23 | -2.6% | news | Stock Titan | Vaxcyte (NASDAQ: PCVX) 2026 proxy on directors, auditor and say-on-pay - Stock Titan |
| 2026-03-27 | +2.5% | news | Stock Titan | Vanguard disaggregates holdings; PCVX ownership shown as 0 (PCVX) - Stock Titan |
| 2023-03-06 | -2.5% | legal | SEC EDGAR | PCVX 8-K: 1.01 (SEC Filing) |
| 2026-02-25 | -2.5% | earnings | Seeking Alpha | Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript |
| 2026-02-25 | -2.5% | analyst | Investing.com | Leerink raises Vaxcyte stock price target on vaccine pipeline expansion - Investing.com |
| 2023-10-04 | +2.5% | legal | SEC EDGAR | PCVX 8-K: 1.01 (SEC Filing) |
| 2026-03-02 | -2.3% | news | Simply Wall St. | Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte’s VAX-31 Shift the Bull Case (PCVX)? |
| 2026-03-02 | -2.3% | news | Barchart | Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. |
| 2026-03-02 | -2.3% | news | Simply Wall St. | Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap Persists |
| 2026-03-02 | -2.3% | executive | Stock Titan | Vaxcyte (PCVX) CFO awarded RSUs and options, surrenders shares for taxes - Stock Titan |
| 2025-02-12 | -2.2% | earnings | Stock Titan | Vaxcyte Sets Stage for Major Q4 Revelations: Vaccine Innovation Updates & Financial Deep-Dive Coming - Stock Titan |
| 2026-01-26 | +2.2% | news | Yahoo Finance | Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations - Yahoo Finance |
| 2024-11-21 | +2.2% | legal | SEC EDGAR | PCVX 8-K: 1.01 and 8.01 (SEC Filing) |
| 2026-04-07 | -2.1% | news | GlobeNewswire | Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference |
| 2026-04-07 | -2.1% | news | Stock Titan | Vaxcyte management joins Needham virtual healthcare event Apr. 14 - Stock Titan |
| 2026-04-07 | -2.1% | news | Stock Titan | Elvia Cowan registers 3,000-share sale (PCVX) after option exercise - Stock Titan |
| 2024-07-02 | -2.0% | legal | SEC EDGAR | PCVX 8-K: 5.02 (SEC Filing) |
| 2026-04-03 | +2.0% | executive | Stock Titan | Vaxcyte (PCVX) COO sells 2,250 shares in planned Rule 10b5-1 trades - Stock Titan |
| 2026-04-15 | -1.9% | news | Cổng thông tin điện tử tỉnh Tây Ninh | Vaxcyte (PCVX) Stock Insider Selling (Edges Lower) 2026-04-15 - Large Cap Trends - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2025-12-22 | +1.9% | news | Yahoo Finance | What Makes Vaxcyte (PCVX) So Attractive - Yahoo Finance |
| 2023-02-27 | -1.7% | legal | SEC EDGAR | PCVX 8-K: 8.01 and (SEC Filing) |
| 2023-02-27 | -1.7% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2026-04-02 | +1.7% | legal | Stock Titan | PCVX SEC Filings - Vaxcyte, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2023-11-27 | +1.6% | legal | SEC EDGAR | PCVX 8-K: 1.01 (SEC Filing) |
| 2026-02-16 | -1.6% | news | Insider Monkey | Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX) - Insider Monkey |
| 2025-12-16 | -1.5% | news | Seeking Alpha | Vaxcyte: Financial Durability And The Case For Disruption |
| 2025-12-16 | -1.5% | news | Seeking Alpha | Vaxcyte: Financial Durability And The Case For Disruption (NASDAQ:PCVX) - Seeking Alpha |
| 2026-02-11 | +1.5% | news | Stock Titan | VAX-31 pneumonia shot enters Phase 3 for previously vaccinated adults - Stock Titan |
| 2023-11-06 | -1.5% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2026-04-08 | -1.5% | earnings | MarketBeat | Insider Selling: Vaxcyte (NASDAQ:PCVX) CAO Sells 3,000 Shares of Stock - MarketBeat |
| 2026-04-08 | -1.5% | executive | Stock Titan | Vaxcyte (PCVX) finance chief sells 3,000 shares after option exercise - Stock Titan |
| 2023-08-08 | -1.4% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2025-07-07 | +1.4% | news | simplywall.st | We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate - simplywall.st |
| 2021-09-20 | +1.4% | legal | SEC EDGAR | PCVX 8-K: 5.02 (SEC Filing) |
| 2025-09-08 | -1.4% | news | Seeking Alpha | Vaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 Transcript |
| 2025-11-12 | +1.4% | legal | Seeking Alpha | Vaxcyte, Inc. (PCVX) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript |
| 2026-03-21 | +1.2% | news | Motley Fool | High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding |
| 2026-03-18 | -1.1% | news | GlobeNewswire | Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate |
| 2026-03-18 | -1.1% | news | Stock Titan | Vaxcyte (PCVX) finance SVP sells 1,892 shares under 10b5-1 plan - Stock Titan |
| 2026-03-18 | -1.1% | news | Stock Titan | A 31-strain pneumonia shot showed strong immune responses in adults 50+ - Stock Titan |
| 2023-04-20 | -1.0% | legal | SEC EDGAR | PCVX 8-K: 8.01 and (SEC Filing) |
| 2022-08-08 | +0.9% | legal | SEC EDGAR | PCVX 8-K: 2.02 and (SEC Filing) |
| 2026-04-13 | +0.9% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | PCVX Q4 2025 Earnings: Vaxcyte Inc. Misses EPS Estimates, Reports No Revenue - Expert Market Insights - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2023-11-28 | -0.9% | legal | SEC EDGAR | PCVX 8-K: 5.02 (SEC Filing) |
| 2026-04-10 | -0.8% | news | Cổng thông tin điện tử Tỉnh Sơn La | Is Vaxcyte (PCVX) Stock Discounted Now | Price at $60.59, Down 1.77% - Collaborative Trading Signals - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-10 | -0.8% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is Vaxcyte (PCVX) Stock Discounted Now | Price at $60.59, Down 1.77% - Investment Community Signals - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-03-23 | -0.8% | news | MT Newswires | Vaxcyte Completes Patient Enrollment in OPUS-1, OPUS-2 Phase-3 Trials for Pneumonia Vaccine |
| 2026-03-23 | -0.8% | news | GlobeNewswire | Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults |
| 2026-03-23 | -0.8% | news | Stock Titan | Vaxcyte fills key adult vaccine trial, sets up 2026 Phase 3 data - Stock Titan |
| 2026-01-01 | +0.5% | news | simplywall.st | Trade Alert: Senior Vice President of Finance Of Vaxcyte Elvia Cowan Has Sold Stock - simplywall.st |
| 2024-12-20 | -0.5% | news | Seeking Alpha | Vaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia asset |
| 2026-04-11 | +0.5% | news | Simply Wall St. | Is It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump? |
| 2026-04-01 | -0.4% | news | Stock Titan | James Wassil sells 7,395 PCVX shares (NASDAQ: PCVX) - Stock Titan |
| 2023-03-02 | -0.3% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Vaxcyte (PCVX) - Zacks Investment Research |
| 2024-03-02 | -0.1% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2023-09-07 | -0.1% | legal | SEC EDGAR | PCVX 8-K: 1.01 (SEC Filing) |
| 2023-10-16 | +0.0% | legal | SEC EDGAR | PCVX 8-K: 1.01 (SEC Filing) |
| 2026-04-26 | — | earnings | MarketBeat | Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat |